BBRP 11001
Alternative Names: BBC-1501; BBRP-11001Latest Information Update: 06 Aug 2024
At a glance
- Originator BenoBio
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Age-related macular degeneration
Most Recent Events
- 06 Aug 2024 Phase-I clinical trials in Age-related macular degeneration (Intravitreous) (BenoBio pipeline, August 2024)
- 12 Apr 2023 Beno Bio plans a phase II trial for Age-related macular degeneration (Intravitreous) in 2025 (BenoBio pipeline, April 2023)
- 07 Apr 2023 Benobio plans a phase I trial for Wet age-related macular degeneration (In adults, In the elderly) in Australia (Intravitreous) in April 2023 (NCT05803785)